INS and type 2 diabetes mellitus: In conclusion, the present study shows that SGLT2 inhibitor treatment in patients with T2D at high risk of CVD attenuates NLRP3 inflammasome activation and secretion of IL-1β, which has a pathogenic effect on both T2D and CVD, in part via increased serum BHB and decreased serum insulin, glucose, and uric acid (Fig. 5).